President-elect Donald Trump threatened Tuesday to place new tariffs on imports from Denmark unless the country gives up control of Greenland, news that dented the stocks of some of Denmark's most ...

We’re dedicating the last day of the year to readers' comments on what the IP landscape would look like to them if a little ...

Just as the COVID pandemic highlighted vulnerabilities in the supply chain, forcing the streamlining ... treatments to patients around the world. Novo Nordisk almost doubles the scale of its ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Compounding pharmacies are allowed to make versions of branded drugs if they are considered to be in short supply by the FDA. Compounded drugs are not FDA approved. Novo Nordisk's (NVO ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for legal issues in China. One of these stocks has a stronger investment ...

To hear Novo tell it, the outsourcing group OFA shouldn’t be allowed to place liraglutide on its compounding list given that FDA-approved generics to Victoza are available. Further, the OFA has ...